A citation-based method for searching scientific literature

Juliette Sandifer Kum-Nji, Aidar R Gosmanov, Helmut Steinberg, Samuel Dagogo-Jack. J Diabetes Complications 2017
Times Cited: 8







List of co-cited articles
68 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin.
Nellowe Candelario, Jedrzej Wykretowicz. Oxf Med Case Reports 2016
23
75


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
62

A Case of Euglycemic Diabetic Ketoacidosis Following Long-term Empagliflozin Therapy.
Peter D Farjo, Kacie M Kidd, Josephine L Reece. Diabetes Care 2016
11
50

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger. Diabetes Care 2015
207
50


Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat Med 2015
418
50

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
462
50



Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.
Junichiro Adachi, Yuusuke Inaba, Chisato Maki. Intern Med 2017
15
50


Recurrent euglycemic diabetic ketoacidosis after discontinuation of sodium-glucose cotransporter 2 inhibitor.
Spyridoula Maraka, Ann E Kearns, Nana Esi N Kittah, Derek T O'Keeffe. Diabetes Res Clin Pract 2016
9
37

Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet.
Tomohide Hayami, Yoshiro Kato, Hideki Kamiya, Masaki Kondo, Ena Naito, Yukako Sugiura, Chika Kojima, Sami Sato, Yuichiro Yamada, Rina Kasagi,[...]. J Diabetes Investig 2015
76
37


Non-occlusive Mesenteric Ischemia with Diabetic Ketoacidosis and Lactic Acidosis Following the Administration of a Sodium Glucose Co-transporter 2 Inhibitor.
Naoki Gocho, Ema Aoki, Chiho Okada, Kazuki Omura, Takeshi Hirashima, Natsuko Suzuki, Hideki Tanaka, Yasue Omori. Intern Med 2016
11
37

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.
Yehuda Handelsman, Robert R Henry, Zachary T Bloomgarden, Sam Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Ele Ferrannini, Vivian A Fonseca, Alan J Garber, George Grunberger,[...]. Endocr Pract 2016
183
37

Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
Anne L Peters, Robert R Henry, Payal Thakkar, Cindy Tong, Maria Alba. Diabetes Care 2016
61
37


Diabetic ketoacidosis precipitated by therapy with antidiabetic agents SGLT2 inhibitors: two cases.
Bala Venkatesh, Geoff Moore, Denzil Gill, Wayne Kelly. Crit Care Resusc 2015
11
37

Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.
Owais Rashid, Saad Farooq, Zareen Kiran, Najmul Islam. BMJ Case Rep 2016
11
37

Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern.
Alehegn Gelaye, Abdallah Haidar, Christina Kassab, Syed Kazmi, Prabhat Sinha. Case Rep Crit Care 2016
17
37

SGLT2 Inhibitors May Predispose to Ketoacidosis.
Simeon I Taylor, Jenny E Blau, Kristina I Rother. J Clin Endocrinol Metab 2015
295
37

Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature.
Jessica Turner, Tahmina Begum, Roger D Smalligan. J Investig Med High Impact Case Rep 2016
10
37

Metabolic ketoacidosis with normal blood glucose: A rare complication of sodium-glucose cotransporter 2 inhibitors.
Saad Ullah, Noman Khan, Hassan Zeb, Hassan Tahir. SAGE Open Med Case Rep 2016
4
75



Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin.
Shreya Pujara, Adriana Ioachimescu. J Investig Med High Impact Case Rep 2017
20
37

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.
Kohei Kaku, Hirotaka Watada, Yasuhiko Iwamoto, Kazunori Utsunomiya, Yasuo Terauchi, Kazuyuki Tobe, Yukio Tanizawa, Eiichi Araki, Masamichi Ueda, Hideki Suganami,[...]. Cardiovasc Diabetol 2014
131
25

Euglycaemic diabetic ketoacidosis.
J F Munro, I W Campbell, A C McCuish, L J Duncan. Br Med J 1973
164
25

SGLT inhibition and euglycaemic diabetic ketoacidosis.
Julia Hine, Heather Paterson, Esha Abrol, David Russell-Jones, Roselle Herring. Lancet Diabetes Endocrinol 2015
55
25

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
155
25

Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.
Bruce A Perkins, David Z I Cherney, Helen Partridge, Nima Soleymanlou, Holly Tschirhart, Bernard Zinman, Nora M Fagan, Stefan Kaspers, Hans-Juergen Woerle, Uli C Broedl,[...]. Diabetes Care 2014
172
25



Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
137
25

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
694
25

Normoglycemic ketoacidosis in a postoperative gastric bypass patient taking canagliflozin.
Fernando B Bonanni, Patrick Fei, Laura L Fitzpatrick. Surg Obes Relat Dis 2016
11
25

Euglycemic diabetic ketoacidosis in pregnancy.
Nauman Tarif, Wisam Al Badr. Saudi J Kidney Dis Transpl 2007
12
25

Euglycaemic ketoacidosis in a postoperative Whipple patient using canaglifozin.
Trevor Wood, Allison J Pang, Julie Hallet, Paul Greig. BMJ Case Rep 2016
10
25

Severe hypercalcemia and hypernatremia in a patient treated with canagliflozin.
Arshpreet Kaur, Stephen J Winters. Endocrinol Diabetes Metab Case Rep 2015
17
25

Incidence of Ketoacidosis in the Danish Type 2 Diabetes Population Before and After Introduction of Sodium-Glucose Cotransporter 2 Inhibitors-A Nationwide, Retrospective Cohort Study, 1995-2014.
Majken Linnemann Jensen, Frederik Persson, Gregers S Andersen, Martin Ridderstråle, John J Nolan, Bendix Carstensen, Marit E Jørgensen. Diabetes Care 2017
25
25

The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis.
Jiao Chen, Fang Fan, J Y Wang, Yang Long, C L Gao, R C Stanton, Yong Xu. Sci Rep 2017
54
25

Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.
Nitesh D Kuhadiya, Husam Ghanim, Aditya Mehta, Manisha Garg, Salman Khan, Jeanne Hejna, Barrett Torre, Antoine Makdissi, Ajay Chaudhuri, Manav Batra,[...]. J Clin Endocrinol Metab 2016
44
25


Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment.
Heidi Storgaard, Jonatan I Bagger, Filip K Knop, Tina Vilsbøll, Jørgen Rungby. Basic Clin Pharmacol Toxicol 2016
28
25

SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.
Gian Paolo Fadini, Benedetta Maria Bonora, Angelo Avogaro. Diabetologia 2017
121
25

Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.
Daisuke Yabe, Masahiro Iwasaki, Hitoshi Kuwata, Takuya Haraguchi, Yoshiyuki Hamamoto, Takeshi Kurose, Kiminobu Sumita, Hitoshi Yamazato, Shigeto Kanada, Yutaka Seino. Diabetes Obes Metab 2017
47
25

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.
Muhammad A Abdul-Ghani, Luke Norton, Ralph A Defronzo. Endocr Rev 2011
283
25



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.